What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Alzheimer's disease
- Disease
Ezio Giacobini mainly investigates Alzheimer's disease, Dementia, Neuroscience, Disease and Cholinergic.
His Alzheimer's disease study combines topics from a wide range of disciplines, such as Memantine, Clinical trial and Cognition, Psychiatry, Neuroimaging.
His studies deal with areas such as Medical literature, Gerontology, Activities of daily living and Subjective report as well as Cognition.
His work on Cognitive decline is typically connected to HIV-associated neurocognitive disorder as part of general Dementia study, connecting several disciplines of science.
His Disease research integrates issues from Precision medicine, Drug development, Reimbursement and Intensive care medicine.
His Cholinergic study combines topics in areas such as Human brain, Acetylcholine and Cholinesterase.
His most cited work include:
- Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. (3383 citations)
- Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. (498 citations)
- Cholinesterase inhibitors: new roles and therapeutic alternatives (417 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Disease, Alzheimer's disease, Neuroscience, Internal medicine and Cholinesterase.
His research integrates issues of Psychiatry, Drug development, Gerontology and Intensive care medicine in his study of Disease.
As a member of one scientific family, he mostly works in the field of Alzheimer's disease, focusing on Cognition and, on occasion, Bioinformatics.
His research in Neuroscience focuses on subjects like Neurodegeneration, which are connected to Atrophy and Cerebral cortex.
His biological study spans a wide range of topics, including Endocrinology, Surgery and Oncology.
His Cognitive disorder and Cognitive decline study, which is part of a larger body of work in Dementia, is frequently linked to Population, bridging the gap between disciplines.
He most often published in these fields:
- Disease (40.26%)
- Alzheimer's disease (36.36%)
- Neuroscience (28.57%)
What were the highlights of his more recent work (between 2011-2021)?
- Disease (40.26%)
- Neuroscience (28.57%)
- Alzheimer's disease (36.36%)
In recent papers he was focusing on the following fields of study:
Disease, Neuroscience, Alzheimer's disease, Cholinergic and Amyloid are his primary areas of study.
His Disease research is multidisciplinary, relying on both Precision medicine, Neuroimaging and Intensive care medicine.
The Neuroimaging study combines topics in areas such as Neurology, Neurodegeneration and Atrophy.
In his study, Cognition is inextricably linked to Clinical trial, which falls within the broad field of Intensive care medicine.
Ezio Giacobini combines subjects such as Solanezumab, Dementia, Cognitive decline, Bapineuzumab and Clinical psychology with his study of Neuroscience.
Cholinergic is closely attributed to Cholinesterase in his research.
Between 2011 and 2021, his most popular works were:
- Clinical trials and late-stage drug development for Alzheimer's disease : an appraisal from 1984 to 2014 (409 citations)
- Alzheimer disease therapy—moving from amyloid-β to tau (278 citations)
- Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers (246 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Alzheimer's disease
Ezio Giacobini spends much of his time researching Disease, Neuroscience, Dementia, Alzheimer's disease and Cognition.
The concepts of his Disease study are interwoven with issues in Neurology, Neuroimaging and Intensive care medicine.
He has researched Neuroscience in several fields, including Solanezumab and Bapineuzumab.
His Dementia study focuses on Cognitive decline in particular.
His research in Alzheimer's disease intersects with topics in Precision medicine, Sex characteristics, Clinical trial, Bioinformatics and Risk factor.
His work deals with themes such as Amyloid deposition, Tau pathology, Amyloid β and Amyloid cascade, which intersect with Cognition.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
